Christiane Gasse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/571485/publications.pdf

Version: 2024-02-01

218677 223800 2,303 66 26 46 h-index citations g-index papers 69 69 69 3584 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Somatic Hospital Contacts, Invasive Cardiac Procedures, and Mortality From Heart Disease in Patients With Severe Mental Disorder. Archives of General Psychiatry, 2009, 66, 713.	12.3	245
2	Chronic Somatic Comorbidity and Excess Mortality Due to Natural Causes in Persons with Schizophrenia or Bipolar Affective Disorder. PLoS ONE, 2011, 6, e24597.	2.5	173
3	Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2010, 71, 103-108.	2.2	114
4	Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2017, 174, 990-998.	7.2	106
5	Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry,the, 2016, 3, 358-366.	7.4	105
6	Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. American Journal of Psychiatry, 2017, 174, 686-694.	7.2	103
7	Frequent use of opioids in patients with dementia and nursing home residents: A study of the entire elderly population of Denmark. Alzheimer's and Dementia, 2015, 11, 691-699.	0.8	82
8	Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia. Schizophrenia Bulletin, 2017, 43, 1064-1069.	4.3	76
9	Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thrombosis and Haemostasis, 2005, 94, 537-543.	3.4	73
10	Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. European Journal of Clinical Pharmacology, 2005, 61, 327-335.	1.9	67
11	Polypharmacy and Potentially Inappropriate Medication in People with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2018, 63, 383-394.	2.6	66
12	The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. American Journal of Psychiatry, 2016, 173, 807-815.	7.2	63
13	Drug interactions in primary care: Impact of a new algorithm on risk determination*1. Clinical Pharmacology and Therapeutics, 2004, 76, 85-96.	4.7	59
14	Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain and Behavior, 2015, 5, e00338.	2.2	55
15	Psychotropic Polypharmacy in Patients withÂDementia: Prevalence and Predictors. Journal of Alzheimer's Disease, 2017, 56, 707-716.	2.6	55
16	Quality markers of drug information on the internet: an evaluation of sites about St. John's Wort. American Journal of Medicine, 2002, 113, 740-745.	1.5	43
17	Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European Neuropsychopharmacology, 2015, 25, 857-863.	0.7	40
18	Inequalities in Access to Treatment and Care for Patients with Dementia and Immigrant Background: A Danish Nationwide Study. Journal of Alzheimer's Disease, 2016, 54, 505-514.	2.6	40

#	Article	IF	CITATIONS
19	Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study. Acta Neuropsychiatrica, 2016, 28, 75-84.	2.1	38
20	Postoperative Treatment of Pain after Hip Fracture in Elderly Patients with Dementia. Dementia and Geriatric Cognitive Disorders, 2016, 41, 181-191.	1.5	38
21	Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. European Journal of Clinical Pharmacology, 2004, 60, 595-602.	1.9	33
22	Lack of Evidence for Association of High Altitude Pulmonary Edema and Polymorphisms of the NO Pathway. High Altitude Medicine and Biology, 2003, 4, 355-366.	0.9	32
23	Time Trends in Antipsychotic Drug Use in Patients with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2015, 49, 211-220.	2.6	32
24	Statin treatment and the risk of depression. Journal of Affective Disorders, 2019, 246, 706-715.	4.1	31
25	Major depression and first-time hospitalization with ischemic heart disease, cardiac procedures and mortality in the general population: A retrospective Danish population-based cohort study. European Journal of Preventive Cardiology, 2014, 21, 532-540.	1.8	30
26	Population Trends in Antihypertensive Drug Use. Journal of Clinical Epidemiology, 1999, 52, 695-703.	5.0	29
27	Selective Serotonin Reuptake Inhibitors and Risk of Acute Pancreatitis. Journal of Clinical Psychopharmacology, 2007, 27, 259-262.	1.4	23
28	Use of Statins and Risk of Hospitalization With Dementia. Alzheimer Disease and Associated Disorders, 2009, 23, 18-22.	1.3	22
29	Do Statins Have Antidepressant Effects?. CNS Drugs, 2017, 31, 335-343.	5.9	22
30	Positive predictive value of a registerâ€based algorithm using the Danish National Registries to identify suicidal events. Pharmacoepidemiology and Drug Safety, 2018, 27, 1131-1138.	1.9	22
31	Antiepileptic Drugs and Suicide: Role of Prior Suicidal Behavior and Parental Psychiatric Disorder. Annals of Neurology, 2019, 86, 951-961.	5.3	19
32	Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia. Schizophrenia Research, 2019, 212, 79-85.	2.0	19
33	Association between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia. Clinical Epidemiology, 2016, Volume 8, 323-332.	3.0	18
34	Inverse association between urbanicity and treatment resistance in schizophrenia. Schizophrenia Research, 2016, 174, 150-155.	2.0	18
35	The Use of Opioids and Antipsychotics in Elderly with Dementia – Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia?. Journal of Alzheimer's Disease, 2020, 73, 259-267.	2.6	18
36	Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. Schizophrenia Research, 2018, 197, 294-297.	2.0	16

#	Article	IF	CITATIONS
37	Predictors of Nonhospitalization and Functional Response in Clozapine Treatment. Journal of Clinical Psychopharmacology, 2017, 37, 148-154.	1.4	15
38	Pharmacogenetics in psychiatric care, a call for uptake of available applications. Psychiatry Research, 2020, 292, 113336.	3.3	15
39	Preâ€diagnostic and postâ€diagnostic psychopharmacological treatment of 16Â288 patients with bipolar disorder. Bipolar Disorders, 2021, 23, 357-367.	1.9	15
40	Risk of Hospitalization for Acute Pancreatitis Associated with Conventional and Atypical Antipsychotics: A Population-Based Case-Control Study. Pharmacotherapy, 2008, 28, 27-34.	2.6	14
41	Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to nonâ€psychotic mania and nonâ€psychotic bipolar depression. Bipolar Disorders, 2017, 19, 505-512.	1.9	14
42	Factors associated with differences in antihypertensive drug treatment: Results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95. International Journal of Public Health, 2002, 47, 128-139.	2.6	13
43	Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 621-630.	2.2	13
44	Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. Translational Psychiatry, 2021, 11, 294.	4.8	13
45	Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities. Journal of the American Geriatrics Society, 2022, 70, 1169-1179.	2.6	13
46	Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from <scp>UK Clinical Practice Research Datalink (CPRD) </scp> and <scp>Danish </scp> national registries (DNR). Pharmacoepidemiology and Drug Safety, 2016, 25, 142-155.	1.9	12
47	Pattern and predictors of sick leave among users of antidepressants: A Danish retrospective register-based cohort study. Journal of Affective Disorders, 2013, 151, 959-966.	4.1	11
48	Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse $\hat{a} \in \hat{u}$ a population-based study of 16,253 incident patients with schizophrenia. Expert Opinion on Pharmacotherapy, 2016, 17, 1055-1062.	1.8	11
49	Geographical Variation in Opioid Use in Elderly Patients with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2019, 70, 1209-1216.	2.6	11
50	The association between first abortion and first-time non-fatal suicide attempt: a longitudinal cohort study of Danish population registries. Lancet Psychiatry,the, 2019, 6, 1031-1038.	7.4	11
51	Geographical Variation in Antipsychotic Drug Use in Elderly Patients with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 2016, 54, 1183-1192.	2.6	10
52	Câ€reactive protein levels and treatment resistance in schizophreniaâ€"A Danish populationâ€based cohort study. Human Psychopharmacology, 2017, 32, e2632.	1.5	10
53	Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence – A Danish nationwide study. Schizophrenia Research, 2018, 199, 116-122.	2.0	10
54	Prescription drug use in pregnancy and variations according to prior psychiatric history. Pharmacoepidemiology and Drug Safety, 2018, 27, 105-113.	1.9	10

#	Article	IF	CITATIONS
55	Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study. Pharmaceuticals, 2022, 15, 870.	3.8	10
56	Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scandinavian Journal of Gastroenterology, 2009, 44, 1288-1295.	1.5	9
57	Association between prior somatic disease and 5-year relapse risk among 11,856 incident patients with schizophrenia. European Psychiatry, 2019, 59, 1-7.	0.2	7
58	Association between global functioning at first schizophrenia diagnosis and treatment resistance. Microbial Biotechnology, 2018, 12, 1198-1202.	1.7	6
59	Declining Use of Potentially Inappropriate Medication in People with Dementia from 2000 to 2015: A Repeated Cross-Sectional Nationwide Register-Based Study. Journal of Alzheimer's Disease, 2021, 79, 1459-1470.	2.6	6
60	The effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: A propensity score matched cohort study. European Neuropsychopharmacology, 2020, 32, 120-130.	0.7	4
61	Cerebrospinal fluid test results and associations with subsequent mental disorders, neurological diseases, and CNS infections: A population-based cohort study. Brain, Behavior, and Immunity, 2021, 98, 210-218.	4.1	4
62	Medical diseases prior to first-time depression diagnosis and subsequent risk of admissions for depression: A nationwide study of 117,585 patients. Journal of Affective Disorders, 2020, 276, 1030-1037.	4.1	3
63	Risk of hospitalization and hip fracture associated with psychotropic polypharmacy in patients with dementia: A nationwide registerâ€based study. International Journal of Geriatric Psychiatry, 2021, 36, 1691-1698.	2.7	3
64	Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark. Pharmacopsychiatry, 2022, 55, 95-107.	3.3	3
65	Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study. Schizophrenia Research, 2022, 246, 268-276.	2.0	1
66	Anti-inflammatory Agents for the Treatment of Depression in the Light of Comorbid Cardiovascular Disease., 2016,, 445-465.		O